NASDAQ · SBFMW

Sunshine Biopharma Inc.

$0.06 +$0.03 (+89.75%) 1D Market open

Key Metrics

$93.84K
Market cap
P/E · TTM
$35.49M
Revenue · TTM
−$6.04M
Net income
EPS · TTM $-3.93
Dividend yield
Free cash flow −$5.86M
Beta · 1Y -0.01
EBITDA · TTM −$5.98M
Gross margin 33.0%

The Story So Far

LAST 6 MONTHS PRIMARY SOURCES ONLY
  • Jul 20
    A material event was filed (Form 8-K).

    8-K - Sunshine Biopharma Inc. (0001402328) (Filer)

    RECEIPT: SEC FORM 8-K, TIMESTAMPED
  • Jul 16
    Money rotated out of high-beta cohorts market-wide.

    High-beta names lagged the blue-chips by 18.6 points over ten sessions around this date. Stocks in that cohort weren't falling alone — they fell together.

    RECEIPT: ROTATION GAUGE, LIVE
  • Jun 23
    The stock moved +123.6% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, Jun 23
  • Jun 10
    The stock moved +98.8% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, Jun 10
  • Jun 9
    From its Feb 25 high, the share price fell 90%.

    Peak close $0.25 on Feb 25; trough close $0.03 on Jun 9. The drawdown is the fact — the chapters around it are the context.

    RECEIPT: PRICE SERIES, PEAK-TO-TROUGH -90%

The story updates itself as events post · The wolf reports; you decide

Snapshot

Market cap
Enterprise value
Shares outstanding
52-wk range$0.02 – $0.65
Avg volume · 20D18.9K
Net cash
Book value / share$14.01
IndustryPharmaceutical Preparations
ExchangeNASDAQ
About Sunshine Biopharma Inc.
IPO dateFeb 15, 2022
Employees50

Sunshine Biopharma Inc is a pharmaceutical company offering and researching life-saving medicines in a wide variety of therapeutic areas, including oncology and antivirals.

Wolf Grade COMING SOON

The wolf is in training. Composite grades vs sector — profitability, health, value, momentum — arrive with the percentile engine. Methodology will be public.

Valuation

P/E
P/S0.00
P/FCF
EV/EBITDA
EV/Sales
Graham №

Profitability

Gross 33.0%
Operating -17.8%
Net -17.0%
FCF -16.5%
ROE / ROIC -26.8% · —

Financial Health

Current ratio4.22
Quick ratio1.98
Debt / equity
Debt / EBITDA
Net cash
Working capital$18.91M

Cash Flow · TTM

Operating CF −$5.69M
Capex −$172.13K
Free cash flow −$5.86M
Buybacks
Dividends paid
Shareholder yield

Piotroski F-Score

4 / 9
Middling fundamentals · 4 of 9 signals passing

Altman Z-Score

-2.5
Distress zone (< 1.81) · elevated risk

Graham Number vs Price

Requires positive earnings and book value
Fundamentals through 2026-03-31 · computed by TickerWolf from SEC filings